Promotion Prospects for 5 Biotech Companies in Regensburg
The bmbf has been supporting innovative biotechnology companies in Germany with the project BioChancePLUS since 2004. The Federal Government has made 100 million Euro available as promotional means until 2006. This enables intensive research development, in particular that of younger biotechnology enterprises, to be promoted and realised more quickly. Currently 60 new research projects of around 30 million € are being promoted throughout the country. In the 2nd round running currently with calls for tenders, 5 biotechnology companies from Regensburg have applied for the position of coordination of BioPark Regensburg GmbH. My means of a group of assessors from the BioRegio Regensburg and external assessors from the bmbf all requirements of the proposal are adhered to, emphasizing once again the highly innovative approach of the young biotechnology scene in Regensburg. The projects themselves:
- Geneart GmbH, founded in 1999, is developing an evolved process, taking HIV as an example, for the generation and selection of special protein building blocks as leading substances for innovative therapeutic agents and vaccines.
- LipoFIT GmbH, founded in 2004, is developing in association with the Institute for Biophysics and Physical Biochemistry of the University of Regensburg and the device manufacturer BRUKER Biospin GmbH from Rheinstetten in Baden-Württemberg a new process for high throughput NMR analysis of body fluids. This makes risk assessment and early recognition of various severe diseases (e.g. arteriosclerosis) accessible to the wider population.
- multimmune GmbH, founded in 1999, is developing a process based on an immune stimulating substance, which could make it possible to immunize patients with tumours against cancer.
- NeuroProfile GmbH, founded in 2001, is identifying new target structures in nerve cells (so-called "neuronal" targets), to develop new types of medicines for neurodegenerative diseases, such as Alzheimer's and Parkinson's disease.
- Profos AG, founded in 2000, is developing a process that can remove cell toxins, which lead to septicaemia, quickly and specifically from the blood. The company is already selling successful products that can remove bacterial endotoxins specifically from biotechnologically relevant solutions.
In autumn 2005 the bmbf is commencing calls for tender for the third and last promotional rounds, with BioPark Regensburg GmbH as coordinator of the BioRegio Regensburg standing once again alongside companies to aid them with their proposals.
For more information see: